natgillin/translations-raw huggingface dataset:
- The CHMP concluded that the Product Information of quetiapine should reflect the current lack of long-term data of quetiapine as add-on treatment of major depressive episodes in patients with major depressive disorder, who have had suboptimal response to initial antidepressant mono-therapy and therefore recommended the amendments to the relevant sections of the Summary of Product Characteristics and Package Leaflet. 
- je CHMP zaključil, da morajo informacije o zdravilu za kvetiapin odražati trenutno odsotnost dolgoročnih podatkov za kvetiapin kot dodatnega zdravljenja velikih depresivnih epizod pri bolnikih z veliko depresivno motnjo, ki so imeli suboptimalen odziv na začetno antidepresivno monoterapijo, in je zato priporočil dopolnilo zadevnih delov povzetka glavnih značilnosti zdravila in navodila za uporabo.
The daily dose at the start of therapy is 50 mg on Day 1 and 2, and 150 mg on Day 3 and 4. 
Dnevni odmerek na začetku zdravljenja je 50 mg 1. in 2. dan ter 150 mg 3. in 4. dan.
10 prolonged-release tablets 30 prolonged-release tablets 50 prolonged-release tablets 60 prolonged-relaease tablets 100 prolonged-release tablets 
10 tablet s podaljšanim sproščanjem 30 tablet s podaljšanim sproščanjem 50 tablet s podaljšanim sproščanjem 60 tablet s podaljšanim sproščanjem 100 tablet s podaljšanim sproščanjem
Keep the Seroquel XR tablets with you. 
S seboj vzemite Seroquel SR tablete.
• treatment of Schizophrenia, including o preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. 
• zdravljenje shizofrenije, vključno s preprečevanjem ponovnega pojava bolezni pri stabilnih shizofreničnih bolnikih, ki se jih vzdržuje z zdravilom Seroquel XR;
At steady-state, the dosenormalized plasma levels of the parent compound, quetiapine, in children and adolescents (10-17 years of age) were in general similar to adults, though Cmax in children was at the higher end of the range observed in adults. 
Za odmerek normalizirana koncentracija matične spojine, kvetiapina, je bila v stanju dinamičnega ravnovesja pri otrocih in mladostnikih (starih od 10 do 17 let) na splošno podobna kot pri odraslih, toda Cmax je bila pri otrocih v zgornjem delu razpona, ugotovljenega pri odraslih.
If you take more Seroquel XR than you should If you take more Seroquel XR than prescribed by your doctor, you may feel sleepy, feel dizzy and experience abnormal heart beats. 
Če ste vzeli večji odmerek zdravila Seroquel SR, kot bi smeli Če ste vzeli večji odmerek zdravila Seroquel SR, kot vam ga je predpisal vaš zdravnik, boste lahko zaspani, omotični ali se vam bo pojavilo nepravilno bitje srca.
Possible risk factors for neutropenia include pre-existing low white cell count (WBC) and history of drug induced neutropenia. 
Med možnimi dejavniki tveganja za nevtropenijo sta že prisotno manjše število levkocitov in anamneza nevtropenije, izzvane z zdravili.
• Take your tablets without food (at least one hour before a meal or at bedtime, your doctor will tell you when. 
• Ne jemljite tablet sočasno s hrano (vzemite jih vsaj eno uro pred obrokom ali pred spanjem.
In such an event, Seroquel XR should be discontinued and appropriate medical treatment given. 
Če se pojavi, je treba zdravljenje z zdravilom Seroquel SR prekiniti in poskrbeti za ustrezno terapijo.
On 22 May 2009, the MAH triggered a referral under Article 6(13) of Commission Regulation (EC) No 1084/2003, requesting the CHMP to consider whether it is appropriate to introduce Seroquel XR, at 50 - 300 mg/day dosage to a population of patients with major depressive disorders, excluding the use as initial treatment and used when patients cannot be appropriately managed on alternative antidepressant treatment. 
Dne 22. maja 2009 je imetnik dovoljenja za promet z zdravilom sprožil postopek napotitve v skladu s členom 6(13) Uredbe Komisije (ES) št. 1084/2003 in zahteval, da Odbor za zdravila za uporabo v humani medicini (CHMP) prouči, ali je primerno uporabljati zdravilo Seroquel XR v odmerku 50-300 mg/dan pri bolnikih z velikimi depresivnimi motnjami, brez uporabe kot začetno zdravljenje in z vključitvijo uporabe, kadar bolnikov ni možno ustrezno zdraviti z alternativnimi antidepresivi.
However in two 10-week placebo controlled quetiapine studies in the same patient population (n=710; mean age: 83 years; range: 56-99 years) the incidence of mortality in quetiapine treated patients was 5.5% versus 3.2% in the placebo group. 
Toda v dveh 10tedenskih s placebom kontroliranih študijah kvetiapina pri isti populaciji bolnikov (n = 710, povprečna starost 83 let, razpon 56-99 let) je bila incidenca umrljivosti med prejemniki kvetiapina 5,5 % in v skupini s placebom 3,2 %.
Extrapyramidal symptoms3 
ekstrapiramidni simptomi3
Long-term efficacy and safety in patients with MDD has not been evaluated as add-on therapy, however long-term efficacy and safety has been evaluated in adult patients as monotherapy (see below). 
Dolgoročna učinkovitost in varnost pri bolnikih z veliko depresivno motnjo nista ocenjeni pri uporabo kot dodatno zdravilo, vendar pa sta bili dolgoročna učinkovitost in varnost ocenjeni pri odraslih bolnikih v monoterapiji (glejte spodaj).
In the schizophrenia study, the difference in LS mean change from baseline in PANSS total score (active minus placebo) was -8.16 for Seroquel 400 mg/day and -9.29 for Seroquel 800 mg/day . 
V študiji shizofrenije je bila razlika v povprečni spremembi po metodi najmanjših kvadratov celotnega seštevka PANSS v primerjavi z izhodiščem (učinkovina minus placebo) -8,16 za Seroquel 400 mg/dan in -9,29 za Seroquel 800 mg/dan.
The CHMP concluded that there is potential benefit in the use of quetiapine as an add-on treatment of major depressive episodes in patients with MDD who have sub-optimal response to antidepressant monotherapy. 
CHMP je zaključil, da obstaja morebitna korist uporabe kvetiapina kot dodatnega zdravljenja velikih depresivnih epizod pri bolnikih z MDD, ki imajo suboptimalen odziv na monoterapijo z antidepresivi.
Based on these in vitro results, it is unlikely that coadministration of quetiapine with other drugs will result in clinically significant drug inhibition of cytochrome P450 mediated metabolism of the other drug. 
Na podlagi teh rezultatov in vitro ni verjetno, da bi sočasna uporaba kvetiapina z drugimi zdravili klinično pomembno zavirala presnovo drugih zdravil s citokromom P450.
Uncommon (affects less than 1 in 100 people): 
Občasni neželeni učinki (pojavijo se pri manj kot 1 od 100 oseb):
Weight gain has been reported in patients who have been treated with quetiapine, and should be monitored and managed as clinically appropriate as in accordance with utilised antipsychotic guidelines (see Sections 4.8 and 5.1). 
Zato je te bolnike treba kontrolirati in jih voditi, kot je klinično primerno in v skladu z uporabljanimi smernicami za antipsihotike (poglavji 4.8 in 5.1).
Quetiapine and norquetiapine also have high affinity at histaminergic and adrenergic α1 receptors, with a lower affinity at adrenergic α2- and serotonin 5HT1A receptors. 
Kvetiapin in norkvetiapin imata tudi veliko afiniteto za histaminske receptorje in adrenergične receptorje α1, manjšo afiniteto pa za adrenergične receptorje α2.
In short-term, placebo-controlled clinical trials in schizophrenia and bipolar mania the aggregated incidence of extrapyramidal symptoms was similar to placebo (schizophrenia: 7.8% for quetiapine and 8.0% for placebo; bipolar mania: 11.2% for quetiapine and 11.4% for placebo). 
V kratkotrajnih, s placebom kontroliranih kliničnih preskušanjih pri shizofreniji in bipolarni maniji je bila skupna incidenca ekstrapiramidnih simptomov podobna kot pri placebu (shizofrenija: 7,8 % s kvetiapinom, 8,0 % s placebom; bipolarna manija: 11,2 % s kvetiapinom in 11,4 % s placebom).
Efficacy Six studies in monotherapy and two add-on treatment studies were submitted by the MAH. 
Imetnik dovoljenja za promet z zdravilom je predložil šest študij monoterapije in dve študiji dopolnilnega zdravljenja.
50 mg tablets are peach coloured; 150 mg tablets are white coloured, 200 mg tablets are yellow coloured; 300 mg tablets are pale yellow coloured and 400 mg tablets are white coloured. 
50 mg tablete so marelične barve, 150 mg tablete so bele barve, 200 mg tablete so rumene barve, 300 mg tablete so bledorumene barve, 400 mg tablete so bele barve.
It is this combination of receptor antagonism with a higher selectivity for 5HT2 relative to D2- receptors, which is believed to contribute to the clinical antipsychotic properties and low extrapyramidal undesirable effect (EPS) liability of Seroquel compared to typical antispychotics. 
Domnevno ta kombinacija antagonističnega delovanja na receptorje in večja selektivnost za receptorje 5HT2 v primerjavi z receptorji D2 prispeva h kliničnim antipsihotičnim lastnostim zdravila Seroquel in majhni nagnjenosti k ekstrapiramidnim neželenim učinkom (EPU).
In both bipolar depression and MDD, the incidence of the individual adverse events (eg, akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia, restlessness, muscle contractions involuntary, psychomotor hyperactivity and muscle rigidity) did not exceed 4% in any treatment group. 
Incidenca posameznih neželenih dogodkov pri bipolarni depresiji in MDD (npr. akatizije, ekstrapiramidne motnje, tremorja, diskinezije, distonije, nemira, nehotnega krčenja mišic, psihomotorične hiperaktivnosti in togosti mišic) v nobeni terapevtski skupini ni presegla 4 %.
Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is contraindicated. 
Sočasna uporaba zaviralcev citokroma P450 3A4, npr. zaviralcev proteaz HIV, azolskih antimikotikov, eritromicina, klaritromicina in nefazodona je kontraindicirana (glejte poglavje 4.5).
• treatment of schizophrenia including preventing relapses in stable schizophrenic patients who have been maintained on Seroquel XR. 
• zdravljenje shizofrenije, vključno s o preprečevanjem relapsa pri shizofrenih bolnikih v stabilni remisiji, ki so na vzdrževalnem zdravljenju z zdravilom Seroquel SR
Seizure 1, Restless legs syndrome, Tardive dyskinesia 1, 6 
konvulzije1, sindrom nemirnih nog, zapoznela diskinezija
In patients receiving a hepatic enzyme inducer, initiation of Seroquel XR treatment should only occur if the physician considers that the benefits of Seroquel XR outweigh the risks of removing the hepatic enzyme inducer. 
Pri bolnikih, ki dobivajo induktor jetrnih encimov, naj bi zdravljenje z zdravilom Seroquel SR uvedli le, če koristi terapije z zdravilom Seroquel SR po zdravnikovi presoji odtehtajo tveganja zaradi opustitve induktorja jetrnih encimov.
• Do not split, chew or crush the tablets. 
• Tablet ne lomite, ne žvečite in ne drobite.
If you are, Seroquel XR should not be taken because the group of medicines that Seroquel XR belongs to may increase the risk of stroke, or in some cases the risk of death, in elderly people with dementia. 
Če ste, ne smete jemati zdravila Seroquel SR, kajti skupina zdravil, v katero spada Seroquel SR, lahko starejšim osebam z demenco poveča tveganje možganske kapi in v nekaterih primerih tveganje smrti,imate vi ali kdo v vaši družini zgodovino nastanka krvnih strdkov, saj so ta zdravila povezana z nastankom krvnih strdkov.
Not all pack sizes may be marketed. 
Vseh navedenih pakiranj ni na trgu.
• If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, 
• Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Fever, severe muscle stiffness, sweating or a lowered level of consciousness (a disorder called “neuroleptic malignant syndrome”). 
Zdravniku morate nemudoma povedati, če se vam pojavijo: zvišana telesna temperatura, huda togost mišic, znojenje ali poslabšanje zavesti (to je motnja, ki jo imenujemo “maligni nevroleptični sindrom”).
Seroquel XR 150 mg and 300 mg/day, given as add-on treatment to ongoing antidepressant therapy (amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine) demonstrated superiority over antidepressant therapy alone in reducing depressive symptoms as measured by improvement in MADRS total score (LS mean change vs. placebo of 2-3.3 points). 
Seroquel SR 150 mg in 300 mg/dan kot dodatek že potekajočemu antidepresivnemu zdravljenju (amitriptilin, bupropion, citalopram, duloksetin, escitalopram, fluoksetin, paroksetin, sertralin ali venlafaksin) je v primerjavi z antidepresivno terapijo samo superiorno zmanjšal depresivne simptome; kot merilo je bilo uporabljeno izboljšanje celotnega seštevka po MADRS (povprečna sprememba po metodi najmanjših kvadratov 2 do 3,3 točke v primerjavi s placebom).
Elevations in blood creatine phosphokinase15 
zvišane vrednosti kreatin-fosfokinaze
It is important that any change in the inducer is gradual, and if required, replaced with a non-inducer (e.g. sodium valproate) (see section 4.4). 
Če je potrebno, ga je treba nadomestiti z neinduktorjem (npr. natrijevim valproatom) (glejte poglavje 4.4).
In short-term clinical trials with Seroquel in paediatric patients (10-17 years of age), 17% of quetiapine treated patients and 2.5% of placebo treated patients gained ≥7% of their body weight. 
V kratkotrajnih kliničnih preskušanjih zdravila Seroquel pri pediatričnih bolnikih (starih od 10 do 17 let) se je telesna masa povečala za ≥ 7 % pri 17 % bolnikov, zdravljenih s kvetiapinom, in pri 2,5 % bolnikov, ki so dobivali placebo.
In a long-term open label study with Seroquel of schizophrenia and bipolar mania, the aggregated incidence of treatment-emergent EPS was 10%. 
Med dolgotrajno odprto študijo Seroquela pri shizofreniji in bipolarni maniji je bila skupna incidenca med zdravljenjem nastalih ekstrapiramidnih simptomov 10 %.
Seroquel XR tablets contain lactose. 
Tablete Seroquel SR vsebujejo laktozo.
Cytochrome P450 (CYP) 3A4 is the enzyme that is primarily responsible for the cytochrome P450 mediated metabolism of quetiapine. 
Encim 3A4 citokroma P450 (CYP) je v prvi vrsti odgovoren za presnovo kvetiapina s citokromom P450.
Two short-term (6 week) studies enrolled patients who had shown an inadequate response to at least one antidepressant. 
Velike depresivne epizode pri veliki depresivni motnji Dve kratkotrajni (6-tedenski) študiji sta vključili bolnike, ki so se neustrezno odzvali na vsaj en antidepresiv.
It is important that any change in the inducer is gradual, and if required, replaced with a non-inducer (e.g. sodium valproate). 
Če je potrebno, ga je treba nadomestiti z neinduktorjem (npr. natrijevim valproatom).
In all clinical trials (placebocontrolled, open-label, active comparator; patients with a baseline neutrophil count ≥1.5 X 109/L), the incidence of at least one occurrence of neutrophil count <0.5 X 109/L was 0.21% in patients treated with quetiapine and 0% in placebo treated patients and the incidence ≥0.5 - <1.0 X 109/L was 0.75% in patients treated with quetiapine and 0.11% in placebo-treated patients. 
V vseh kliničnih preskušanjih (s placebom kontroliranih, odprtih in s primerjalno učinkovino; bolniki z izhodiščnim številom nevtrofilcev ≥ 1,5 x 109/l) je bila incidenca vsaj enega pojava števila nevtrofilcev < 0,5 x 109/l 0,21 % pri bolnikih, ki so dobivali kvetiapin, in 0 % pri tistih, ki so dobivali placebo, incidenca števila ≥ 0,5 do < 1,0 x 109/l pa je bila 0,75 % pri bolnikih, ki so dobivali kvetiapin, in 0,11 % pri tistih, ki so dobivali placebo.
NO- Norway AstraZeneca AS, Hoffsveien 70B, (PO Box 200), 
AstraZeneca AS, Hoffsveien 70B, (PO Box 200), 0319 Oslo, Norveška
50 mg, 150 mg 200 mg, 300 mg and 400 mg tablets 
150-mg, 200-mg, 300-mg in 400-mg tablete
Reproductive system and breast disorders Rare: 
Motnje reprodukcije in dojk Redki:
ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 
DODATEK III POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
In the treatment of moderate to severe manic episodes, Seroquel demonstrated superior efficacy to placebo in reduction of manic symptoms at 3 and 12 weeks, in two monotherapy trials. 
Pri zdravljenju zmernih do hudih epizod manije je kvetiapin v dveh preskušanjih monoterapije po 3 in 12 tednih manične simptome zmanjšal učinkoviteje kot placebo.
In shorter-term placebo controlled clinical studies of patients with major depressive episodes in bipolar disorder an increased risk of suicide-related events was observed in young adults patients (younger than 25 years of age) who were treated with quetiapine as compared to those treated with placebo (3.0% vs. 0%, respectively). 
V kratkotrajnih s placebom kontroliranih kliničnih študijah bolnikov z depresijo pri bipolarni motnji so ugotovili večje tveganje s samomorom povezanih dogodkov pri mladih odraslih bolnikih (mlajših od 25 let), ki so prejemali kvetiapin (3,0 %), kot pri tistih, ki so prejemali placebo (0 %).
BE - Belgium NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel 
BE - Belgija NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel
Based on the above, the benefit risk is considered positive for Seroquel XR as add-on treatment of major depressive episodes in patients with major depressive disorder, who have had suboptimal response to initial antidepressant mono-therapy subject to conditions of the marketing authorisation. 
Na podlagi zgoraj navedenega se meni, da je razmerje med tveganjem in koristmi pozitivno za zdravilo Seroquel XR kot dodatno zdravljenje velikih depresivnih epizod pri bolnikih z veliko depresivno motnjo, ki so imeli suboptimalen odziv na začetno antidepresivno monoterapijo v skladu s pogoji dovoljenja za promet z zdravilom.
In a short-term placebo-controlled monotherapy trial with Seroquel in children and adolescent patients (10-17 years of age) with bipolar mania, the aggregated incidence of extrapyramidal symptoms was 3.6% for quetiapine and 1.1% for placebo. 
V kratkotrajnem, s placebom kontroliranem preskušanju monoterapije z zdravilom Seroquel pri otrocih in mladostnikih (starih od 10 do 17 let) z bipolarno manijo je bila skupna incidenca ekstrapiramidnih simptomov 3,6 % med uporabo kvetiapina in 1,1 % med uporabo placeba.
For patients who were randomized to quetiapine, the mean weight gain during the open label period was 2.56 kg, and by week 48 of the randomized period, the mean weight gain was 3.22 kg, compared to open label baseline. 
Pri bolnikih, randomiziranih na kvetiapin, je bilo povprečno povečanje telesne mase med odprtim obdobjem 2,56 kg, do 48. tedna randomiziranega obdobja pa je bilo povprečno povečanje telesne mase 3,22 kg v primerjavi z izhodiščem odprtega obdobja.
It is also not recommended to consume grapefruit juice while on quetiapine therapy. 
Prav tako ni priporočljivo jemati grenivkinega soka, ko jemljete kvetapin.
Eosinophilia, Thrombocytopenia 
eozinofilija, trombocitopenija
Seroquel XR is indicated for: 
Zdravilo Seroquel SR je indicirano za:
Switching from Seroquel immediate-release tablets: 
Prehod s tablet Seroquel filmsko obložene tablete:
In 4 additional clinical trials with quetiapine, with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, Seroquel IR 300 mg and 600 mg was significantly superior to placebo treated patients for the relevant outcome measures: mean improvement on the MADRS and for response defined as at least a 50% improvement in MADRS total score from baseline. 
V 4 dodatnih 8-tedenskih kliničnih preskušanjih s kvetiapinom pri bolnikih z zmernimi do hudimi depresivnimi epizodami pri bipolarni motnji I ali II je bilo zdravilo Seroquel v odmerkih 300 mg in 600 mg statistično značilno boljši od placeba pri relevantnih merilih izida: povprečnem izboljšanju MADRS in odzivu, opredeljenem kot izboljšanje celotnega seštevka MADRS za vsaj 50 % v primerjavi z izhodiščem.
PACKAGE LEAFLET 
zamegljen vid
For add-on treatment of major depressive episodes in MDD: 
Kot dodatno zdravljenje velikih depresivnih epizod pri veliki depresivni motnji:
Erythromycin or clarithromycin (for infections). 
• eritromicin, klaritromicin (zdravila proti okužbam), • nefazodon (zdravilo proti depresiji).
Seroquel data in combination with divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited; however, combination therapy was well tolerated. 
Podatki o uporabi kvetiapina v kombinaciji z valproatom ali litijem pri zdravljenju obdobij zmerne do hude manije po 3 in 6 tednih so sicer pomanjkljivi, toda kombinirano zdravljenje so bolniki dobro prenašali.
Elevations in total cholesterol (predominantly LDL cholesterol) 12, Decreases in HDL cholesterol18, Weight gain9 
zvišanje koncentracije serumskih trigliceridov11 zvišanje koncentracij celokupnega holesterola (predvsem holesterola LDL)12, znižanje holesterola HDL18, povečanje telesne mase9
A 26-week open-label extension to the acute trials (n= 380 patients), with Seroquel flexibly dosed at 400-800 mg/day, provided additional safety data. 
Dodatni podatki o varnosti izvirajo iz 26-tedenskega odprtega nadaljevanja akutnih preskušanj (n = 380 bolnikov), med katerim so zdravilo Seroquel uporabljali v prilagodljivih odmerkih od 400 do 800 mg na dan.
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel Belgium 
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel Belgija
Azole medicines (for fungal infections). 
• nekatera zdravila proti glivičnim okužbam (iz skupine azolov),
Quetiapine exhibits minimal dystonic liability in haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration. 
Pri opicah vrste Cebus, senzibiliziranih s haloperidolom ali naivnih za zdravila, kaže kvetiapin po akutni in kronični uporabi minimalno distonično nagnjenost.
COUNTRY 
Država
In short-term placebo-controlled trials with Seroquel in paediatric patients with bipolar mania, the incidence of suicide related events was 1.0% (2/193) for quetiapine and 0% (0/90) for placebo in patients <18 years of age. 
V kratkotrajnih s placebom kontroliranih preskušanjih zdravila Seroquel pri pediatričnih bolnikih z bipolarno manijo je bila incidenca s samomorom povezanih dogodkov med bolniki, starimi < 18 let, 1,0 % (2/193) pri kvetiapinu in 0 % (0/90) pri placebu.
Concomitant use of quetiapine and thioridazine caused an increased clearance of quetiapine with approx. 70%. 
Sočasna uporaba kvetiapina in tioridazina je povečala očistek kvetiapina za približno
• Discontinuation symptoms (symptoms which occur when you stop taking Seroquel XR) include not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick 
• odtegnitveni sindrom (simptomi, ki se pojavijo po prenehanju jemanja zdravila Seroquel SR), ki vključuje težave s spanjem (nespečnost), slabost, glavobol, drisko, bruhanje, omotico in razdražljivost.
The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor). 
Sočasna uporaba antidepresivov imipramina (znan zaviralec CYP 2D6) ali fluoksetina (znan zaviralec CYP 3A4 in CYP 2D6) ni bistveno spremenila farmakokinetike kvetiapina.
The most commonly noted adverse reactions with quetiapine were dry mouth, sedation, and somnolence while nausea and headache were more commonly noted with the active controls. 
Najpogosteje opaženi neželeni učinki kvetiapina so bili suha usta, umirjenost in zaspanost, slabost in glavobol pa je bilo pogosteje opaziti pri zdravilnih kontrolnih substancah.
The incidence of relapse was 14.2% for Seroquel XR treated patients and 34.4% for placebotreated patients. 
Pri bolnikih, ki so dobivali zdravilo Seroquel SR, je bila incidenca recidivov 14,2 %, pri bolnikih, ki so dobivali placebo, pa 34,4 %.
All prolonged-release tablets are capsule shaped and marked with XR and the strength. 
Izgled zdravila Seroquel SR in vsebina pakiranja Vse tablete s podaljšanim sproščanjem so ovalne oblike in označene z znakom »XR« in jakostjo.